Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX Market Closed
Market Cap: 440.4B GBX
Have any thoughts about
Dechra Pharmaceuticals PLC?
Write Note
Section:
 

Relative Value

The Relative Value of one DPH stock under the Base Case scenario is 102.15 GBX. Compared to the current market price of 3 866 GBX, Dechra Pharmaceuticals PLC is Overvalued by 97%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DPH Relative Value
Base Case
102.15 GBX
Overvaluation 97%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

578.3
P/S
P/S
Price to Sales
578.3
vs History
52
vs Industry
2
Median 3Y
578.3
Median 5Y
584.6
Industry
2.5
Forward
517.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
2
Median 3Y
5 046.2
Median 5Y
7 527.5
Industry
21.8
Forward
2 980
More Details
6 923.9
P/OCF
P/OCF
Price to OCF
6 923.9
vs History
0
vs Industry
0
Median 3Y
6 405.7
Median 5Y
4 019.8
Industry
16.1
More Details
2 143.3
P/FCFE
P/FCFE
Price to FCFE
2 143.3
vs History
41
vs Industry
0
Median 3Y
2 143.3
Median 5Y
2 143.3
Industry
23.8
More Details
583.1
P/B
P/B
Price to Book Value
583.1
vs History
42
vs Industry
0
Median 3Y
583.1
Median 5Y
583.1
Industry
2.1
More Details
578.8
EV/S
EV/S
Enterprise Value to Sales
578.8
vs History
52
vs Industry
1
Median 3Y
578.8
Median 5Y
585.2
Industry
2.7
Forward
517.8
More Details
1 026
EV/GP
EV/GP
Enterprise Value to Gross Profit
1 026
vs History
49
vs Industry
0
Median 3Y
1 026
Median 5Y
1 026
Industry
5.2
More Details
3 846.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
3 846.3
vs History
42
vs Industry
0
Median 3Y
3 768.8
Median 5Y
3 846.3
Industry
13.5
Forward
1 926.1
More Details
17 702.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
17 702.3
vs History
0
vs Industry
100
Median 3Y
6 562.5
Median 5Y
5 830
Industry
16.8
Forward
2 795.1
More Details
6 930.6
EV/OCF
EV/OCF
Enterprise Value to OCF
6 930.6
vs History
0
vs Industry
0
Median 3Y
6 407.9
Median 5Y
4 020.7
Industry
15.2
More Details
13 236.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13 236.9
vs History
0
vs Industry
0
Median 3Y
11 688.6
Median 5Y
6 957.8
Industry
19.3
More Details
326.4
EV/IC
EV/IC
Enterprise Value to IC
326.4
vs History
53
vs Industry
0
Median 3Y
326.4
Median 5Y
344.4
Industry
1.9
More Details

Multiples Across Competitors

DPH Competitors Multiples
Dechra Pharmaceuticals PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.3B USD 18.5 90.4 48.5 54.2
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
349.7B USD 4 23.8 11.5 15
US
Merck & Co Inc
NYSE:MRK
251.6B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
199.5B CHF 3.4 17.3 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4.1 31.4 168.9 253.1
CH
Novartis AG
SIX:NOVN
171.3B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.5 35.6 10.6 16
IE
Endo International PLC
LSE:0Y5F
147.1B USD 63.5 -50.3 236.2 592.2
P/S Multiple
Revenue Growth P/S to Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average P/S: 382 947.7
578.3
29%
19.9
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
IE
E
Endo International PLC
LSE:0Y5F
63.5
N/A N/A
P/E Multiple
Earnings Growth P/E to Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average P/E: 32.4
Negative Multiple: -15 783.5 		N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.4
446%
0.2
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.8
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.3
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.4
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -50.3 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average EV/EBITDA: 437.2
3 846.3
151%
25.5
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
168.9
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
IE
E
Endo International PLC
LSE:0Y5F
236.2
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average EV/EBIT: 1 869.3
17 702.3
675%
26.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.1
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2
IE
E
Endo International PLC
LSE:0Y5F
592.2
N/A N/A

See Also

Summary
DPH intrinsic value, competitors valuation, and company profile.
DCF Valuation
DPH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DPH stock valuation using valuation multiples.
Wall Street Estimates
DPH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DPH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.